Driehaus Capital Management LLC Sells 681,366 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Driehaus Capital Management LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 47.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 760,841 shares of the company’s stock after selling 681,366 shares during the quarter. Driehaus Capital Management LLC owned about 2.27% of TransMedics Group worth $47,438,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group during the fourth quarter worth approximately $31,000. Hager Investment Management Services LLC acquired a new position in TransMedics Group in the fourth quarter valued at about $33,000. Sachetta LLC acquired a new stake in TransMedics Group during the fourth quarter worth about $40,000. AlphaQuest LLC bought a new position in TransMedics Group in the 4th quarter valued at about $52,000. Finally, Arcadia Investment Management Corp MI bought a new stake in shares of TransMedics Group during the 4th quarter worth approximately $72,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Up 2.7 %

TMDX opened at $95.89 on Thursday. The company has a fifty day moving average of $77.20 and a two-hundred day moving average of $76.01. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of 102.01 and a beta of 1.91.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TMDX shares. Piper Sandler reaffirmed an “overweight” rating and issued a $105.00 target price (up previously from $90.00) on shares of TransMedics Group in a report on Tuesday, April 29th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $124.20.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.